---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-089497"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2021-07-06T23:59:59+00:00"
generated_at: "2026-06-30T07:06:34.350037+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eloxx updates Phase 2 ELX-02 progress; COO Neil Belloff to depart by Aug 25

## Summary
- Neil Belloff, COO and General Counsel, will transition and depart on or before August 25, 2021; will receive base salary and benefits through departure.
- Phase 2 study of ELX-02 for cystic fibrosis: sufficient enrollment to assess biological activity; data from first four arms expected Q4 2021.
- Fifth treatment arm added to evaluate ELX-02 in combination with Kalydeco (ivacaftor).
- No drug-related serious adverse events reported; dose escalation proceeded to top dose level.

## SEC filing metadata
- accession: 0001104659-21-089497
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2021-07-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465921089497/0001104659-21-089497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465921089497/tm2121565d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-089497
- JSON: https://secwatch.observer/filing/0001104659-21-089497.json
- Plain text: https://secwatch.observer/filing/0001104659-21-089497.txt

## Key facts
- Executive change
  Neil Belloff departed as Chief Operating Officer and General Counsel at Eloxx Pharmaceuticals, Inc..
  - Action: depart
  - Role: Chief Operating Officer and General Counsel
  source text: Neil Belloff, Chief Operating Officer and General Counsel of the Company, agreed that Mr. Belloff would transition his responsibilities as Chief Operating Officer and General Counsel prior to his departure from the Company on or prior to August 25, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465921089497/0001104659-21-089497-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.